MedTrace Logo

Zevalin Twice in Aggressive Non-Hodgkin Lymphoma

NCT00902525 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2012-12-31

No results posted yet for this study

Summary

Despite of the availability of treatment for this disease, this study is justified because no known therapies are really curative and it is necessary to look for new treatment options to improve the clinical outcome and prognosis of relapsed aggressive lymphoma. This study is designed for patients not eligible for high-dose chemotherapy and autologous stem cells transplantation.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

90Y-Ibritumomab Tiuxetan

All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan

Sponsors & Collaborators

  • Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

    collaborator OTHER

  • Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

    lead OTHER

Principal Investigators

  • Barbara Botto, MD · SCDO Ematologia AOU San Giovanni Battista Torino

  • Umberto Vitolo, MD · SCDO Ematologia 2 AOU San Giovanni Battista Torino

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-01-31
Completion
2011-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902525 on ClinicalTrials.gov